This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gibson, C. M. Articles by Kunadian, V. Search for Related Content PubMed PubMed Citation Articles by Gibson, C. M. Articles by Kunadian, V. Related Collections Cardiovascular Pharmacology Platelet function inhibitors Acute coronary syndromes Acute myocardial infarction

(Circulation. 2008;118:6-8.)
© 2008 American Heart Association, Inc.

Editorial

Intracoronary Administration of Abciximab in ST-Elevation Myocardial Infarction

C. Michael Gibson, MS, MD; Cafer Zorkun, MD, PhD; Vijayalakshmi Kunadian, MBBS, MD, MRCP

From the Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.

Reprint requests to C. Michael Gibson, MS, MD, 350 Longwood Ave, First Floor, Boston, MA 02115. E-mail mgibson@perfuse.org

Key Words: Editorials • angioplasty • microcirculation • myocardial infarction

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Primary percutaneous coronary intervention (PCI) is now the preferred method of treating patients with ST-elevation myocardial infarction (STEMI). Despite restoration of epicardial flow, microvascular obstruction may persist after primary PCI as a result of both atheromatous and thrombotic embolization, neutrophil plugging, edema, and vasospasm.^1–3 Therefore, studies such as the one by Thiele et al⁴ in this issue of Circulation that focus on the prevention and treatment of microvascular dysfunction are informative with respect to the means to improve the primary PCI strategy.

Article p 49

There have been efforts to identify mechanical and pharmacological strategies to improve myocardial perfusion after primary PCI. Compared with the systemic administration of intravenous pharmacotherapies, highly localized administration of intracoronary pharmacotherapy may be associated with a several-hundred-fold increase in the local concentration of an agent in the epicardial artery and microcirculation. A number of pharmacotherapies, including adenosine,^5,6 calcium channel blockers,⁷ -blockers,⁸ β₂-receptor activators,⁹ other vasodilators, antithrombotics,^10,11 and antiplatelet agents,^12–14 have been used to treat microvascular dysfunction.

There are tens of thousands of glycoprotein IIb/IIIa (GPIIb/IIIa) receptors on the platelet surface.¹⁵ Platelet receptor occupancy studies have demonstrated that if there are fewer GPIIb/IIIa receptors free and available for cross-linking with fibrinogen, then myocardial perfusion is improved.¹⁶ To estimate the number of GPIIb/IIIa receptors available for cross-linking, the absolute platelet count has been multiplied by the percent of receptors available to cross link to calculate an index of the absolute number of GPIIb/IIIa receptors available. The absolute number of GPIIb/IIIa receptors available for cross-linking is reduced . . . [Full Text of this Article]

This article has been cited by other articles:

				B. S. Coller and S. J. Shattil The GPIIb/IIIa (integrin {alpha}IIb{beta}3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend Blood, October 15, 2008; 112(8): 3011 - 3025. [Abstract] [Full Text] [PDF]

				Intracoronary Versus Intravenous Abciximab Delivery Journal Watch Cardiology, July 30, 2008; 2008(730): 3 - 3. [Full Text]